Braltus 10 Microgram Per Delivered Dose Inhalation Powder Hard Capsule
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Braltus 10 microgram per delivered dose inhalation powder, hard capsule
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 16 micrograms of tiotropium bromide, equivalent to
13 micrograms of tiotropium.
The delivered dose (the dose that leaves the mouthpiece of the Zonda inhaler) is 10 micrograms of tiotropium per capsule
Excipient with known effect
Each capsule contains 18 milligrams lactose monohydrate.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Inhalation powder, hard capsule.
Colourless and transparent, size 3 capsules, containing white powder.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Braltus is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).
Braltus is indicated for use in adults.
4.2 Posology and method of administration
Posology
Route of administration: Inhalation use.
Recommended Dose
Adults 18 years of age and older:
Inhalation of the contents of one capsule once daily with the Zonda inhaler. Inhalation should be at the same time of day each day.
The recommended dose should not be exceeded.
The delivered dose of a single capsule (10 micrograms) is sufficient and is the standard dose for treatment with Braltus..
Braltus capsules are for inhalation only; they must not be swallowed.
Braltus capsules must only be inhaled with the Zonda inhaler.
Special populations
Elderly patients can use tiotropium bromide at the recommended dose.
Patients with mild renal impairment (creatinine clearance >50 ml/min) can use tiotropium bromide at the recommended dose. For patients with moderate to severe impairment (creatinine clearance <50 ml/min) see section 4.4 and section 5.2.
Hepatically impaired patients can use tiotropium bromide at the recommended dose (see section 5.2).
Paediatric population
Braltus should not be used in children or adolescents under 18 years of age. Safety and efficacy have not been established. No data are available.
There is no relevant use for tiotropium bromide in the paediatric population for the indication of COPD.
The safety and efficacy of tiotropium bromide in cystic fibrosis in children and adolescents aged less than 18 years have not been established. No data are available.
Method of administration/instructions for Use and Handling To ensure proper administration of the medicinal product, the patient should be trained in the use of the inhaler by either the prescribing physician or by other healthcare professionals.
The Zonda inhaler is especially designed for Braltus capsules; patients must not use it to take any other medication. Braltus capsules must only be inhaled using the Zonda inhaler. Patients must not use any other inhalers to take Braltus capsules.
The Zonda inhaler should only be used with the bottle of capsules provided. Do not reuse the inhaler for another bottle of capsules. Discard the Zonda device after 30 uses 15 uses if used on conjunction with the 15 capsule presentation)
2. Mouthpiece
3. Base
4. Piercing button
5. Centre chamber
1. Pull the cap upwards.
2. Hold the base of the inhaler firmly and open the mouthpiece by pulling it upwards, in the direction of the arrow to open it.
3. Remove a Braltus capsule from the bottle immediately before use and close the bottle tightly. Place one capsule in the capsule-shaped compartment in the base of the inhaler. Do not store the capsule in the Zonda inhaler.
4. Never place a capsule directly into the mouthpiece.
5. Close the mouthpiece until a click is heard, leaving the cap open.
6. Hold the inhaler with the mouthpiece upwards, and press the piercing button completely in only once. Release the button. This will pierce the capsule and allows the medication to be released when the patient breathes in.
7. Breathe out fully. It is important to do this away from the mouthpiece. Avoid breathing into the mouthpiece at any time.
8. Place the mouthpiece in your mouth and keep your head in an upright posistion. Close your lips around the mouthpiece and breathe in slowly and deeply enough to hear or feel the capsule vibrating inside the compartment. Hold your breathe for as long as you comfortably can whilst taking the inhaler out of your mouth. Then breathe normally. Repeat steps 7 and 8 to empty the capsule completely.
8
9. After use, open the mouthpiece again, and tip out the empty capsule. Close the mouthpiece and cap, and store the Zonda inhaler.
nr
Braltus capsules contain only a small amount of powder, so that the capsule is only partially filled.
If necessary, the patient may wipe the mouthpiece of the Zonda inhaler after use with a dry cloth or tissue.
4.3 Contraindications
Hypersensitivity to the active substance tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium, or to any of the excipients listed in section 6.1, including lactose monohydrate which contains milk protein.
4.4 Special warnings and precautions for use
Tiotropium bromide, as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy.
Immediate hypersensitivity reactions may occur after administration of tiotropium bromide inhalation powder.
Consistent with its anticholinergic activity, tiotropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. (see section 4.8).
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a
rapid-acting bronchodilator and should be treated straightaway. Braltus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Tiotropium should be used with caution in patients with recent myocardial infarction <6 months; any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year; hospitalisation for heart failure (NYHA Class III or IV) within the past year. These patients were excluded from the clinical trials and these conditions may be affected by the anticholinergic mechanism of action.
As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance <50 ml/min), tiotropium bromide should be used only if the expected benefit outweighs the potential risk.There is no long term experience in patients with severe renal impairment (see section 5.2).
Patients should be cautioned to avoid getting the drug powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately.
Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries.
Tiotropium bromide should not be used more frequently than once daily (see section 4.9).
Each capsule contains 18 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The excipient lactose may contain trace amounts of milk proteins which may cause reactions in those with severe hypersensitivity or allergy to milk protein.
4.5 Interaction with other medicinal products and other forms of interaction
Although no formal drug interaction studies have been performed, tiotropium bromide inhalation powder has been used concomitantly with other drugs without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, commonly used in the treatment of COPD.
Use of long-acting p2 agonists (LABA) or inhaled corticosteroids (ICS) was not found to alter the exposure to tiotropium.
The co-administration of tiotropium bromide with other anticholinergic drugs has not been studied and is therefore not recommended.
4.6 Fertility, pregnancy and lactation
Fertility
Clinical data on fertility are not available for tiotropium. A non-clinical study performed with tiotropium showed no indication of any adverse effect on fertility (see section 5.3).
Pregnancy
There is a very limited amount of data from the use of tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses (see 5.3). As a
precautionary measure, it is preferable to avoid the use of Braltus during pregnancy.
Breast-feeding
It is unknown whether tiotropium bromide is excreted in human breast milk. Despite studies in rodents which have demonstrated that excretion of tiotropium bromide in breast milk occurs only in small amounts, use of tiotropium bromide is not recommended during breast-feeding. Tiotropium bromide is a long-acting compound. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Braltus should be made taking into account the benefit of breast-feeding to the child and the benefit of Braltus therapy to the woman.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.
4.8 Undesirable effects
Many of the listed undesirable effects can be assigned to the anticholinergic properties of tiotropium bromide.
The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.e. events attributed to tiotropium) observed in the tiotropium group (9,647 patients) from 28 pooled placebo-controlled clinical trials with treatment periods ranging from four weeks to four years.
Frequency is defined using the following convention:
Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data)
|
System Organ Class/MedDRA Preferred Term |
Frequency |
|
Metabolism and nutrition disorders Dehydration |
Not known |
|
Nervous system disorders Dizziness Headache Taste disorders |
Uncommon Uncommon Uncommon |
|
Insomnia |
Rare |
|
Eye disorders | |
|
Vision blurred |
Uncommon |
|
Glaucoma |
Rare |
|
Intraocular pressure increased |
Rare |
|
Cardiac disorders | |
|
Atrial fibrillation |
Uncommon |
|
Supraventricular tachycardia |
Rare |
|
Tachycardia |
Rare |
|
Palpitations |
Rare |
|
Respiratory, thoracic and mediastinal disorders | |
|
Pharyngitis |
Uncommon |
|
Dysphonia |
Uncommon |
|
Cough |
Uncommon |
|
Bronchospasm |
Rare |
|
Epistaxis |
Rare |
|
Laryngitis |
Rare |
|
Sinusitis |
Rare |
|
Gastrointestinal disorders | |
|
Dry mouth |
Common |
|
Gastrooesophageal reflux disease |
Uncommon |
|
Constipation |
Uncommon |
|
Oropharyngeal candidiasis |
Uncommon |
|
Intestinal obstruction, including ileus paralytic |
Rare |
|
Gingivitis |
Rare |
|
Glossitis |
Rare |
|
Dysphagia |
Rare |
|
Stomatitis |
Rare |
|
Nausea |
Rare |
|
Dental caries |
Not known |
|
Skin and subcutaneous tissue disorders, immune | |
|
system disorders |
Uncommon |
|
Rash |
Rare |
|
Urticaria |
Rare |
|
Pruritus |
Rare |
|
Hypersensitivity (including immediate reactions) |
Rare |
|
Angioedema |
Not known |
|
Anaphylactic reaction |
Not known |
|
Skin infection, skin ulcer |
Not known |
|
Dry skin | |
|
Musculoskeletal and connective tissue disorders | |
|
Joint swelling |
Not known |
|
Renal and urinary disorders | |
|
Dysuria |
Uncommon |
|
Urinary retention |
Uncommon |
|
Urinary tract infection |
Rare |
Allergic reactions
The excipient lactose may contain trace amounts of milk proteins which may cause reactions in those with severe hypersensitivity or allergy to milk protein.
Tiotropium bromide should be discontinued immediately if a hypersensitivity or allergic reaction occurs and the patient should then be managed in the usual way.
Paradoxical bronchospasm
As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a
rapid-acting bronchodilator and should be treated straightaway. Braltus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Description of selected adverse reactions
In controlled clinical studies, the commonly observed undesirable effects were anticholinergic undesirable effects such as dry mouth which occurred in approximately 4% of patients.
In 28 clinical trials, dry mouth led to discontinuation in 18 of 9,647 tiotropium treated patients (0.2%).
Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation and intestinal obstruction including ileus paralytic as well as urinary retention.
Other special population
An increase in anticholinergic effects may occur with increasing age.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
High doses of tiotropium bromide may lead to anticholinergic signs and symptoms.
However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340 microgram tiotropium bromide in healthy volunteers. Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7 day dosing of up to 170 microgram tiotropium bromide in healthy volunteers. In a multiple dose study in COPD patients with a maximum daily dose of 43 microgram tiotropium bromide over four weeks no significant undesirable effects have been observed.
Acute intoxication by inadvertent oral ingestion of tiotropium bromide capsules is unlikely due to low oral bioavailability.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other drugs for obstructive airway diseases, inhalants, anticholinergics ATC code: R03B B04
Mechanism of action
Tiotropium bromide is a long-acting, specific, muscarinic receptor antagonist, in clinical medicine often called an anticholinergic. By binding to the muscarinic receptors in the bronchial smooth musculature, tiotropium bromide inhibits the cholinergic (bronchoconstrictive) effects of acetylcholine, released from parasympathetic nerve endings. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, tiotropium bromide competitively and reversibly antagonises the M3 receptors, resulting in relaxation. The effect was dose dependent and lasted longer than 24 hours.
The long duration is probably due to the very slow dissociation from the M3 receptor, exhibiting a significantly longer dissociation half-life than ipratropium. As an N-quaternary anticholinergic, tiotropium bromide is topically (broncho-) selective when administered by inhalation, demonstrating an acceptable therapeutic range before systemic anticholinergic effects may occur.
Pharmacodynamic effects
The bronchodilation is primarily a local effect (on the airways), not a systemic one. Dissociation from M2-receptors is faster than from M3, which in functional in vitro studies, elicited (kinetically controlled) receptor subtype selectivity of M3 over M2. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD.
Cardiac electrophysiology
Electrophysiology: In a dedicated QT study involving 53 healthy volunteers, tiotropium 18 microgram and 54 microgram (i.e. three times the therapeutic dose) over 12 days did not significantly prolong QT intervals of the ECG.
Clinical efficacy and safety
The clinical development programme included four one-year and two six-month randomised, double-blind studies in 2663 patients (1308 receiving tiotropium bromide). The one-year programme consisted of two placebo-controlled trials and two trials with an active control (ipratropium). The two six-month trials were both, salmeterol and placebo controlled. These studies included lung function and health outcome measures of dyspnea, exacerbations and health-related quality of life.
Lung function
Tiotropium bromide, administered once daily, provided significant improvement in lung function (forced expiratory volume in one second, FEV1 and forced vital capacity, FVC) within 30 minutes following the first dose which was maintained for 24 hours. Pharmacodynamic steady state was reached within one week with the majority of bronchodilation observed by the third day. Tiotropium bromide significantly improved morning and evening PEFR (peak expiratory flow rate) as measured by patient's daily recordings. The bronchodilator effects of tiotropium bromide were maintained throughout the one year period of administration with no evidence of tolerance.
A randomised, placebo-controlled clinical study in 105 COPD patients demonstrated that bronchodilation was maintained throughout the 24 hour dosing interval in comparison to placebo regardless of whether the drug was administered in the morning or in the evening.
Clinical trials (up to 12 months)
Dyspnoea, Exercise tolerance
Tiotropium bromide significantly improved dyspnea (as evaluated using the Transition Dyspnea Index.). This improvement was maintained throughout the treatment period.
The impact of improvements in dyspnea on exercise tolerance was investigated in two randomised, double-blind, placebo-controlled trials in 433 patients with moderate to severe COPD. In these trials, six weeks of treatment with tiotropium bromide significantly improved symptom-limited exercise endurance time during cycle ergometry at 75% of maximal work capacity by 19.7% (Trial A) and 28.3% (Trial B) compared with placebo).
Health-related Quality of Life
In a 9-month, randomized, double-blind, placebo-controlled clinical trial of 492 patients, tiotropium bromide improved health-related quality of life as determined by the St. George's Respiratory Questionnaire (SGRQ) total score. The proportion of patients treated with tiotropium which achieved a meaningful improvement in the SGRQ total score (i.e. > 4 units) was 10.9% higher compared with placebo (59.1% in the tiotropium bromide groups vs. 48.2% in the placebo group (p=0.029)). The mean difference between the groups was 4.19 units (p=0.001; confidence interval: 1.69 - 6.68). The improvements of the subdomains of the SGRQ-score were 8.19 units for “symptoms”, 3.91 units for “activity” and 3.61 units for “impact on daily life”. The improvements of all of these separate subdomains were statistically significant.
COPD Exacerbations
In a randomized, double-blind, placebo controlled trial of 1,829 patients with moderate to very severe COPD, tiotropium bromide statistically significantly reduced the proportion of patients who experienced exacerbations of COPD (32.2% to 27.8%) and statistically significantly reduced the number of exacerbations by 19% (1.05 to 0.85 events per patient year of exposure). In addition, 7.0% of patients in the tiotropium bromide group and 9.5% of patients in the placebo group were hospitalized due to a COPD exacerbation (p=0.056). The number of hospitalizations due to COPD was reduced by 30% (0.25 to 0.18 events per patient year of exposure).
A one-year randomised, double-blind, double-dummy, parallel-group trial compared the effect of treatment with 18 microgram tiotropium once daily with that of 50 microgram salmeterol HFA pMDI twice daily on the incidence of moderate and severe exacerbations in 7,376 patients with COPD and a history of exacerbations in the preceding year.
Table 1: Summary ^ of exacerbation ^ endpoints
|
Endpoint |
Tiotropium 18 microgram inhalation powder4 N = 3707 |
Salmeterol 50 microgram HFA pMDI N = 3669 |
Ratio (95% CI) |
p-value |
|
Time [days] to first exacerbation1 |
187 |
145 |
0.83 (0.77 0.90) |
<0.001 |
|
Time to first severe (hospitalised) exacerbation2 |
- |
- |
0.72 (0.61 0.85) |
<0.001 |
|
Patients with >1 exacerbation, n (%)3 |
1277 (34.4) |
1414 (38.5) |
0.90 (0.85 0.95) |
<0.001 |
|
Patients with >1 severe (hospitalised) exacerbation, n (%)3 |
262 (7.1) |
336 (9.2) |
0.77 (0.66 0.89) |
<0.001 |
1 Time [days] refers to 1st quartile of patients. Time to event analysis was done using Cox's proportional hazards regression model with (pooled) centre
and treatment as covariate; ratio refers to hazard ratio.
2
Time to event analysis was done using Cox's proportional hazards regression model with (pooled) centre and treatment as covariate; ratio refers to hazard ratio. Time [days] for the 1st quartile of patients cannot be calculated, because proportion of patients with severe exacerbation is too low.
3 Number of patients with event were analysed using Cochran-Mantel-Haenszel test stratified by pooled centre; ratio refers to risk ratio.
4 Tiotropium 18 microgram inhalation powder delivers 10 microgram tiotropium
Compared with salmeterol, tiotropium bromide increased the time to the first exacerbation (187 days vs. 145 days), with a 17% reduction in risk (hazard
ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P<0.001). Tiotropium bromide also increased the time to the first severe (hospitalised) exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P<0.001).
Long-term clinical trials (more than 1 year, up to 4 years)
In a 4-year, randomised, double-blind, placebo-controlled clinical trial of 5,993 randomised patients (3,006 receiving placebo and 2,987 receiving tiotropium bromide), the improvement in FEV1 resulting from tiotropium bromide, compared with placebo, remained constant throughout 4 years. A higher proportion of patients completed > 45 months of treatment in the tiotropium bromide group compared with the placebo group (63.8% vs.
55.4%, p<0.001). The annualized rate of decline of FEV1 compared to placebo was similar between tiotropium bromide and placebo. During treatment, there was a 16% reduction in the risk of death. The incidence rate of death was 4.79 per 100 patient years in the placebo group vs. 4.10 per 100 patient years in the tiotropium group (hazard ratio (tiotropium/placebo) = 0.84, 95% CI = 0.73, 0.97). Treatment with tiotropium reduced the risk of respiratory failure (as recorded through adverse event reporting) by 19% (2.09 vs. 1.68 cases per 100 patient years, relative risk (tiotropium/placebo) = 0.81, 95% CI = 0.65, 0.999).
Tiotropium active-controlled study
A long-term, large scale randomised, double-blind, active-controlled study with an observation period up to 3 years has been performed to compare the efficacy and safety of tiotropium bromide inhalation powder and tiotropium bromide soft mist inhaler (5,694 patients receiving tiotropium bromide inhalation powder; 5,711 patients receiving tiotropium bromide soft mist inhaler). The primary endpoints were time to first COPD exacerbation, time to all-cause mortality and in a sub-study (906 patients) trough FEV1 (pre-dose). The time to first COPD exacerbation was numerically similar during the study with tiotropium bromide inhalation powder and tiotropium bromide soft mist inhaler (hazard ratio (tiotropium bromide inhalation powder/ tiotropium bromide soft mist inhaler) 1.02 with a 95% CI of 0.97 to 1.08). The median number of days to the first COPD exacerbation was 719 days for tiotropium bromide inhalation powder and 756 days for tiotropium bromide soft mist inhaler.
The bronchodilator effect of tiotropium bromide inhalation powder was sustained over 120 weeks, and was similar to tiotropium bromide soft mist inhaler. The mean difference in trough FEV1 for tiotropium bromide inhalation powder versus tiotropium bromide soft mist inhaler was 0.010 L (95% CI -0.018 to 0.038 L).
In the post-marketing study comparing tiotropium bromide soft mist inhaler and tiotropium bromide inhalation powder, all-cause mortality including vital status follow up was similar during the study with tiotropium bromide inhalation powder and tiotropium bromide soft mist inhaler (hazard ratio (tiotropium bromide inhalation powder/tiotropium bromide soft mist inhaler) 1.04 with a 95% CI of 0.91 to 1.19).
Paediatric population
The European Medicines Agency has waived the obligation to submit results of studies with tiotropium bromide in all subsets of the paediatric population
in COPD and cystic fibrosis (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties
Tiotropium bromide is a non-chiral quaternary ammonium compound and is sparingly soluble in water. Tiotropium bromide is administered by dry powder inhalation. Generally with the inhaled route of administration, the majority of the delivered dose is deposited in the gastro-intestinal tract, and to a lesser extent in the intended organ of the lung. Many of the pharmacokinetic data described below were obtained with higher doses than recommended for therapy.
Absorption
Following dry powder inhalation by young healthy volunteers, the absolute bioavailability of 19.5% suggests that the fraction reaching the lung is highly bioavailable. Oral solutions of tiotropium have an absolute bioavailability of 2-3%. Maximum tiotropium plasma concentrations were observed 5-7 minutes after inhalation.
At steady state, peak tiotropium plasma levels in COPD patients were 12.9 pg/ml and decreased rapidly in a multicompartmental manner. Steady state trough plasma concentrations were 1.71 pg/ml. Systemic exposure following the inhalation of tiotropium bromide inhalation powder was similar to tiotropium inhaled via the soft mist inhaler.
Distribution
Tiotropium has a plasma protein binding of 72% and shows a volume of distribution of 32 L/kg. Local concentrations in the lung are not known, but the mode of administration suggests substantially higher concentrations in the lung. Studies in rats have shown that tiotropium bromide does not penetrate the blood-brain barrier to any relevant extent.
Biotransformation
The extent of biotransformation is small. This is evident from a urinary excretion of 74% of unchanged substance after an intravenous dose to young healthy volunteers. The ester tiotropium bromide is nonenzymatically cleaved to the alcohol (N-methylscopine) and acid compound (dithienylglycolic acid) that are inactive on muscarinic receptors. In-vitro experiments with human liver microsomes and human hepatocytes suggest that some further drug (<20% of dose after intravenous administration) is metabolised by cytochrome P450 (CYP) dependent oxidation and subsequent glutathionconjugation to a variety of Phase II-metabolites.
In vitro studies in liver microsomes reveal that the enzymatic pathway can be inhibited by the CYP 2D6 (and 3A4) inhibitors, quinidine, ketoconazole and gestodene. Thus CYP 2D6 and 3A4 are involved in metabolic pathway that is responsible for the elimination of a smaller part of the dose. Tiotropium bromide even in supra-therapeutic concentrations does not inhibit CYP 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1 or 3A in human liver microsomes.
Elimination
The effective half-life of tiotropium ranges between 27-45h in COPD patients. Total clearance was 880 ml/min after an intravenous dose in young healthy volunteers. Intravenously administered tiotropium is mainly excreted unchanged in urine (74%). After dry powder inhalation by COPD patients in steady-state, urinary excretion is 7% (1.3 micrograms) of the unchanged drug over 24 hours, the remainder being mainly non-absorbed drug in gut that is eliminated via the faeces. The renal clearance of tiotropiumexceeds the creatinine clearance, indicating secretion into the urine. After chronic once daily inhalation by COPD patients, pharmacokinetic steady state was reached by day 7 with no accumulation thereafter.
Linearity/non-linearity
Tiotropium demonstrates linear pharmacokinetics in the therapeutic range independent of the formulation.
Special patient populations
Older people: As expected for all predominantly renally excreted drugs, advanced age was associated with a decrease of tiotropium renal clearance (365 mL/min in COPD patients <65 years to 271 mL/min in COPD patients >65 years). This does not result in a corresponding increase in AUC0-6,ss or
Cmax,ss values.
Renal impairment: Following once daily inhaled administrations of tiotropium to steady-state COPD patients, mild renal impairment (CLcr 50-80 mL/min) resulted in slightly higher AUC0-6,ss (between 1.8-30% higher) and similar Cmax,ss values compared to patients with normal renal function (CLCR >80 mL/min)..
In COPD patients with moderate to severe renal impairment (CLcr <50 mL/min) the intravenous administration of tiotropium resulted in doubling of the total exposure (82% higher AUC0-4h and 52% higher Cmax) compared to COPD patients with normal renal functions, which was confirmed by plasma concentrations after dry powder inhalation.
Hepatic impairment: Liver insufficiency is not expected to have any relevant influence on tiotropium pharmacokinetics. Tiotropium is predominantly cleared by renal elimination (74% in young healthy volunteers) and simple non-enzymatic ester cleavage to pharmacologically inactive products.
Japanese COPD Patients: In cross trial comparison, mean peak tiotropium plasma concentrations 10 minutes postdosing at steady-state were 20% to 70% higher in Japanese compared to Caucasian COPD patients following inhalation of tiotropium but there was no signal for higher mortality or cardiac risk in Japanese patients compared to Caucasian patients. Insufficient pharmacokinetic data is available for other ethnicities or races.
Paediatric population: See section 4.2
Pharmacokinetic/pharmacodynamic relationship
There is no direct relationship between pharmacokinetics and
pharmacodynamics.
5.3 Preclinical safety data
Many effects observed in conventional studies of safety pharmacology, repeated dose toxicity, and reproductive toxicity could be explained by the anticholinergic properties of tiotropium bromide. Typically in animals reduced food consumption, inhibited body weight gain, dry mouth and nose, reduced lacrimation and salivation, mydriasis and increased heart rate were observed. Other relevant effects noted in repeated dose toxicity studies were: mild irritancy of the respiratory tract in rats and mice evinced by rhinitis and epithelial changes of the nasal cavity and larynx, and prostatitis along with proteinaceous deposits and lithiasis in the bladder in rats.
Harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development could only be demonstrated at maternally toxic dose levels. Tiotropium bromide was not teratogenic in rats or rabbits. In a general reproduction and fertility study in rats, there was no indication of any adverse effect on fertility or mating performance of either treated parents or their offspring at any dosage.
The respiratory (irritation) and urogenital (prostatitis) changes and reproductive toxicity were observed at local or systemic exposures more than five-fold the therapeutic exposure. Studies on genotoxicity and carcinogenic potential revealed no special hazard for humans.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate (which contains milk protein)
Capsule composed of hydroxypropylmethylcellulose (HPMC), commonly known as Hypromellose.
6.2
Incompatibilities
Not applicable
6.3 Shelf life
24 months
After first opening: 30 days (15 capsule bottle) or 60 days (30 capsule bottle)
6.4 Special precautions for storage
Keep the bottle tightly closed. Store in the original package to protect from moisture.
Do not refrigerate or freeze.
6.5 Nature and contents of container
High density polyethylene (HDPE) bottles closed with polypropylene (PP) screw-caps with polyethylene (PE) safety ring and Low density polyethylene (LDPE) desiccant capsule containing silica gel. Each bottle contains 15 or 30 capsules, supplied in a carton with a Zonda inhaler.
The Zonda inhaler is a single dose inhalation device with a green body and cap and a white push button,made from acrylonitrile butadiene styrene (ABS) plastic materials and stainless steel.
Multipacks containing either 60 capsules (2 packs of 30), and 2 Zonda inhalers or 90 capsules (3 packs of 30), and 3 Zonda inhalers.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
7
TEVA UK Limited, Brampton Road, Hampden Park, Eastbourne,
East Sussex, BN22 9AG UNITED KINGDOM
8 MARKETING AUTHORISATION NUMBER(S)
PL 00289/1870
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
24/06/2016
10 DATE OF REVISION OF THE TEXT
24/06/2016